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Glucagon receptor (Gcgr) signalingmaintains hepatic
glucoseproduction during the fasting state; however,
the importance of the Gcgr for lipidmetabolism is un-
clear.Weshowhere that fastedGcgr/miceexhibit
a significant increase in hepatic triglyceride secretion
and fasting increases fatty acid oxidation (FAO) in
wild-type (WT) but not in Gcgr/ mice. Moreover
fasting upregulated the expression of FAO-related
hepatic mRNA transcripts in Gcgr+/+ but not in
Gcgr/ mice. Exogenous glucagon administration
reduced plasma triglycerides in WT mice, inhibited
TG synthesis and secretion, and stimulated FA beta
oxidation in Gcgr+/+ hepatocytes. The actions of
glucagon on TG synthesis and FAO were abolished
in PPARa/ hepatocytes. These findings demon-
strate that the Gcgr receptor is required for control
of lipid metabolism during the adaptive metabolic
response to fasting.
INTRODUCTION
Glucagon, a peptide of 29 amino acids released from pancreatic
a cells is the principal counterregulatory hormone that opposes
the actions of insulin. Glucagon stimulates gluconeogenesis
and promotes glycogenolysis leading to liberation of glucose
from hepatocytes. These actions of glucagon are transduced
via a G protein-coupled receptor (GPCR) (the glucagon receptor
or Gcgr), a member of the class II GPCR superfamily (Mayo et al.,
2003). Glucagon action in the liver maintains normoglycemia in
the fasted state via activation of a Gs protein, leading to the stim-
ulation of adenylate cyclase activity, cAMP production, Epac,
Torc2, PKA, and CREB activation (Jelinek et al., 1993; Koo
et al., 2005; Wakelam et al., 1986). Glucagon also increases
intracellular calcium in a phospholipase C dependent manner
(Aromataris et al., 2006; Jelinek et al., 1993; Wakelam et al.,
1986) and activates AMPK (Kimball et al., 2004) p38 MAPK
(Cao et al., 2005; Chen et al., 1998) and JNK (Chen et al., 1998),
through mechanisms that remain incompletely understood.
The control of glucagon secretion is dysregulated in human
subjects with type 2 diabetes (T2DM) (Raskin and Unger, 1978;
Unger, 1971), fostering efforts directed at suppression of gluca-Cellgon action for the treatment of T2DM. Indeed, diminution of glu-
cagon action leads to reductions in blood glucose and improve-
ment in glucose control in preclinical studies (Jiang and Zhang,
2003; Johnson et al., 1982; Unson et al., 1989). Moreover, tran-
sient reduction of hepatic Gcgr expression in diabetic rodents
was associated with significant improvements in glucose control
(Liang et al., 2004; Sloop et al., 2004), and genetic inactivation of
the Gcgr in mice is associated with mild fasting hypoglycemia,
improved glucose tolerance, and resistance to diet-induced
obesity (Conarello et al., 2007; Gelling et al., 2003). Taken
together, these studies confirm the importance of Gcgr signaling
in the control of glucose homeostasis.
Improvement of metabolic control in the setting of glucose in-
tolerance or experimental diabetes through attenuation of gluca-
gon action has been associated with reduction in hepatic lipid
accumulation and reduced levels of circulating triglycerides
and free fatty acids (Conarello et al., 2007; Liang et al., 2004).
Nevertheless, glucagon administration in the absence of diabe-
tes produces potent hypolipemic actions (Bobe et al., 2003a; Ea-
ton, 1973; Guettet et al., 1991) including decreased triglyceride
(TG) and very low density lipoproteins (VLDL) release by the liver
(Bobe et al., 2003a; Guettet et al., 1989), reduced levels of
plasma cholesterol (Guettet et al., 1988, 1989) and stimulation
of hepatic free fatty acid (FFA) beta oxidation (Prip-Buus et al.,
1990). Indeed, exogenous glucagon reduces liver triacylglycerol
content and prevents the development of fatty liver in dairy cows
(Bobe et al., 2003b, 2006; Nafikov et al., 2006), whereas reduced
glucagon action is associated with the development of fatty liver
(Charbonneau et al., 2005a, 2005b).
As the mechanisms linking Gcgr action to the control of lipid
synthesis and/or FFA oxidation are poorly understood, we have
now examined the importance of Gcgr signaling for lipid synthe-
sis, secretion, and oxidation in Gcgr+/+ and Gcgr/mice. Our
data provide new evidence implicating the Gcgr as an important
integrator of metabolic signals converging on the peroxisome
proliferator-activated receptor (PPARa), leading to regulation of
multiple components of hepatocyte lipid metabolism.
RESULTS
The Gcgr Is Required for Control of Hepatic TG
Secretion
To assess the importance of Gcgr signaling for the regulation of
plasma lipids, we measured circulating levels of TGs and FFA in
Gcgr/ and Gcgr+/+ littermate control mice after fasting. NoMetabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc. 359
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Glucagon Action and Lipid MetabolismFigure 1. Glucagon Decreases Levels of Plasma TGs and Inhibits Hepatic TG Secretion In Vivo
(A–F) TG (A and D) and FFA (B and E) levels were determined in plasma fromGcgr/male mice, and Gcgr+/+ littermate controls fasted for 5 or 16 hr (A and B) or
fromWT males treated with glucagon for 24 hr (30 ng/g body weight) as described in the Experimental Procedures (D and E). In (C) and (F), hepatic TG secretion
was assessed indirectly bymeasurement of plasma TGs after intravenous injection of TritonWR-1339 inGcgr/mice and +/+ littermate controls fasted for 16 hr
(C), or WT males following a single glucagon injection, 30 ng/g BW as described in the Experimental Procedures (F). Values in each panel are expressed as
mean ± SEM n = 4–11 mice per group. * = p < 0.05; ** or # = p < 0.01; *** = p < 0.001. ### = p < 0.001.difference was observed in levels of plasma TGs and FFA in male
Gcgr/ versus Gcgr+/+ mice after 5 hr of fasting (Figures 1A
and 1B), and TG levels were further reduced by 28% in Gcgr+/+
mice after 16 hr of fasting (Figure 1A). Unexpectedly, Gcgr/
mice exhibited a marked increase in plasma TGs and FFA after
a 16 hr fast (Figures 1A and 1B, p < 0.001; and Figures S1A
and S1B). Hepatic TG secretion, assessed following administra-
tion of tritonWR1339 (Otway and Robinson, 1967; Scanu, 1965),
was also significantly increased in male (Figure 1C, p < 0.001)
and female Gcgr/mice (Figure S1C). Consistent with findings
in Gcgr/ mice, exogenous glucagon administration signifi-
cantly decreased levels of plasma TGs and FFA in both male360 Cell Metabolism 8, 359–371, November 5, 2008 ª2008 Elsevier(Figures 1D and 1E) and female (Figures S1D and S1E) Gcgr+/+
mice. Similarly, glucagon inhibited hepatic TG secretion by 20%
in male (Figure 1F, p < 0.001) and 30% in female (Figure S1F)
Gcgr+/+ mice.
The effects of glucagon on plasma lipids were not secondary
to stimulation of insulin secretion, as levels of plasma insulin level
and glucose were appropriately lower after fasting in both
Gcgr+/+ and Gcgr/ mice (Figures S2A and S2B), and gluca-
gon administration significantly increased glycemia (Figure S2D)
but produced only modest increases in levels of plasma insulin
(Figure S2C). Moreover, unlike the effects of exogenous gluca-
gon (Figure 1F), which reduced TG secretion, insulinInc.
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TG secretion (Figure S2E). Similarly, while glucagon directly in-
hibited both TG synthesis and secretion in murine hepatocytes
in vitro, insulin exerted opposite stimulatory effects (Figures
S2G and S2H). Therefore, the inhibitory effects of glucagon on
TG synthesis and secretion are not likely mediated through stim-
ulation of insulin secretion.
To elucidate themechanisms important for glucagon action on
lipid metabolism, we analyzed p38 MAPK and AMPK, signaling
molecules known to be important for the regulation of hepatic
lipid metabolism. Glucagon rapidly and transiently stimulated
both AMPK and p38 MAPK phosphorylation in murine hepato-
cytes (Figures 2A and 2B, respectively). Moreover, glucagon
stimulated p38 MAPK activity and the p38 MAPK inhibitor
SB203580 and the AMPK inhibitor (AMPKi) (but not the PKA in-
hibitor H89) prevented the glucagon-stimulated increase in p38
MAPK activity (Figure 2C).
Glucagon Inhibits TG Synthesis and Secretion via
Distinct Pathways
We next investigated the glucagon-regulated control of hepato-
cyte TG synthesis and secretion in murine hepatocytes. Gluca-
Figure 2. Glucagon Activates p38 MAPK in an AMPK-
Dependent Manner
(A and B) Primary mouse hepatocytes fromWTmice were cul-
tured with or without 20 nM glucagon, following which total
cell lysates were prepared and subjected to western blot
analysis as described in the Experimental Procedures. * = p <
0.05, *** = p < 0.001 for levels of phosphorylated proteins in the
presence or absence of glucagon.
(C) Mouse hepatocytes were cultured for 30 min with or with-
out 20 nM glucagon in the presence or absence of 2 mM H89,
10 mM SB203580, or 20 mM AMPKi. All data are mean ± SEM,
n = 6. * = p < 0.01 for values obtained in the presence or
absence of glucagon.
gon had no effect on the intracellular levels of newly
synthesized FFA in hepatocytes (Figure 3A), but
significantly inhibited both TG synthesis
(Figure 3B, p < 0.001) and secretion (Figure 3C,
p < 0.001). The inhibitory actions of glucagon on
both TG synthesis and secretion were not dimin-
ished by the PKA inhibitor H89 (Figures 3B and
3C, respectively). In contrast, the glucagon-medi-
ated inhibition of TG synthesis (Figure 3B), but not
secretion (Figure 3C), was abolished following
pharmacological inhibition of either p38 MAPK or
AMPK. Similarly, glucagon was not able to inhibit
TG synthesis but still inhibited TG secretion (Fig-
ures S3B and S3C) following shRNA-mediated
knockdown (by about 50%, Figure S3A) of
p38MAPK and AMPK expression in hepatocytes.
FFA beta oxidation in liver homogenates from
fasted and fed mice was monitored as conversion
of 1-14C palmitate to 14CO2, which increases line-
arly in hepatocytes as the rate of beta oxidation
increases (Giordano et al., 2005). Fasting increased
hepatic FFA oxidation in Gcgr+/+ mice (Figure 3D,
1.25 ± 0.05 mmol/g liver/hr in fed versus 1.84 ± 0.1 mmol/g liver/
hr in fastedmice, p < 0.01). In contrast, FFA oxidation failed to in-
crease and paradoxically decreased in fasting Gcgr/ mice
(Figure 3D, 1.84 ± 0.1 mmol/g liver/hr versus 0.53 ± 0.08 mmol/g
liver/hr in fasted Gcgr+/+ versus Gcgr/ mice, respectively,
p < 0.001). Moreover, FFA oxidation was also significantly lower
in fed Gcgr/ mice (Figure 3D; p < 0.05, 1.25 ± 0.05 mmol/g
liver/hr in Gcgr+/+ versus 0.92 ± 0.04 mmol/g liver/hr in Gcgr/
mice, p < 0.01). The glucagon-stimulated increase in FFA
beta oxidationwas completely abolished by the p38MAPK inhib-
itor SB203580 (Figure 3E), and no beta oxidation of fatty acids
was detectable under basal or glucagon-stimulated conditions
when hepatocytes were pretreated with AMPKi (Figure 3E). Re-
duction of p38MAPK and AMPK expression using shRNA also
abrogated the glucagons-stimulated increase in FAO oxidation
(Figure S3D).
To determine whether the inhibitory effect of glucagon on TG
synthesismay be indirect, perhaps reflecting reduced availability
of FFA due to enhanced glucagon-stimulated fatty acid oxida-
tion, we examined whether inhibition of fatty acid oxidation
results in increased levels of FFA available for TG synthesis. He-
patocytes were incubated with 1 mM etomoxir, an irreversibleCell Metabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc. 361
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Glucagon Action and Lipid MetabolismFigure 3. Glucagon Modulates Hepatic TG Synthesis and Secretion and FFA Beta Oxidation
(A–H)Lipid synthesis was assessed bymeasurement of FFAs and TGs in WT hepatocytes (A, B, C, F, G, and H) treated for 16 hr with or without 20 nM glucagon in
the presence or absence of 10 mMSB203580, 2 mMH89, or 20 mMAMPKi (A–C) or 1 mMetomoxir (F–H). Lipids were extracted from themedia (secretion) or cells +
media (synthesis), separated by TLC, and quantified by scintillation counting. Data are mean ± SEM of four independent experiments. * = p < 0.05, ** = p < 0.01,
*** = p < 0.001 for values obtained in the presence or absence of glucagon. Beta oxidation of [1-14C]-palmitate assessed in liver homogenates were prepared from
Gcgr/ or littermate controls fed or fasted for 24 hr (D),a nd in primary hepatocytes from WT mice treated with or without 20 nM glucagon for 24 hr in the
presence or absence of 10 mM SB203580 or 20 mM AMPKi (E), as described in the Experimental Procedures. Data are mean ± SEM of six independent
experiments. * = p < 0.05, ** = p < 0.01 for fasted versus the fed state in (D) and for vehicle versus glucagon treated cells in (E); ## = p < 0.01, ### = p < .001
for Gcgr+/+ versus Gcgr/ mice in (D).CPT1a antagonist known to inhibit FAO (Hiyoshi et al., 2003). Al-
though glucagon alone had no significant effect on levels of FFAs
in murine hepatocytes, glucagon stimulated a significant in-362 Cell Metabolism 8, 359–371, November 5, 2008 ª2008 Elseviercrease in levels of FFAs in hepatocytes treated with etomoxir
(Figure 3F). Moreover, glucagon no longer inhibited TG synthesis
but continued to inhibit TG secretion in the presence of etomoxirInc.
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thesis by increasing FFA beta oxidation, thereby decreasing the
availability of FFA for TG secretion.
To understand the mechanism(s) by which glucagon modu-
lates the adaptation of hepatic lipidmetabolism to fasting, we an-
alyzed hepatic gene expression profiles in fastedGcgr+/+ versus
Gcgr/mice. Fasting increased levels of mRNA transcripts for
multiple genes important for control of fatty acid beta oxidation in
male and female Gcgr+/+mice (Figures 4A and S4A). In contrast,
levels of several mRNA transcripts of genes important for FAO
were modestly increased in Gcgr/ mice (compare Figures
4A and 4B), and more prolonged fasting in Gcgr/ mice failed
to upregulate levels of hepatic mRNA transcripts for Facl2,
Derc2, CPT2, Acadm, Ehadh, Hadha, Hadhb (Figures 4B and
S4B). Consistent with the importance of glucagon for changes
in hepatic gene expression during fasting, exogenous adminis-
tration of glucagon toWTmice produced a hepatic gene expres-
sion profile comparable to that detected during fasting, with sig-
nificant increases in levels of mRNA transcripts for multiple
genes involved in fatty acid beta oxidation (Figures 4C and S4C).
In contrast to the importance of the Gcgr for fasting-related
changes in genes regulating FAO, the expression of genes regu-
lating fatty acid synthesis was similarly decreased in Gcgr+/+
and Gcgr/ mice during fasting (Figures 4D, 4E, S4D, and
S4E). Furthermore, exogenous glucagon administration did not
produce a reduction in levels of mRNA transcripts for the major-
ity of genes regulating fatty acid synthesis (Figures 4F and S4F).
These findings demonstrate that the Gcgr is essential for control
of a genetic program regulating fatty acid beta oxidation; how-
ever, Gcgr signaling is not essential for control of genes regulat-
ing fatty acid synthesis.
Glucagon Stimulates PPARaActivity in a p38MAPK- and
AMPK-Dependent Manner
Asmany of the glucagon-regulated genes important for fatty acid
b oxidation (Figures 4 and S4) are known targets of PPARa (Pat-
souris et al., 2006), we assessed the role of PPARa as a down-
stream target for glucagon action. Levels of liver PPARa mRNA
transcripts were comparable in fasted Gcgr/ versus Gcgr+/+
mice (Figure 5A), and exogenous glucagon produced a modest
but nonsignificant increase in levels of PPARamRNA transcripts
in WT mice (Figure 5B). Furthermore, hepatic PPARa protein
levels increased to similar levels during fasting in both Gcgr+/+
and Gcgr/ mice (Figure 5C). However, glucagon administra-
tionwasassociatedwith amarked redistribution inPPARa immu-
noreactivity from the cytoplasm to hepatocyte nuclei (Figure 5D,
lower panel). Furthermore, fasting was associated with nuclear
translocation of PPARa in liver of Gcgr+/+ mice, but not in
Gcgr/ mice, in which considerable amounts of PPARa re-
mained in the cytoplasm (Figure 5E).Moreover, fasting increased
the binding of PPARa to a peroxisome proliferator response ele-
ment (PPRE) in EMSA studies using liver nuclear extracts from
Gcgr+/+ mice but not in extracts from fasted Gcgr/ mice
(Figure 5F).
To understand the mechanisms by which PPARa remains in
the cytoplasm under the fed state, we investigated the interac-
tion of PPARa with the chaperone protein HSP90. Under resting
conditions PPARa is bound to HSP90 in the cytoplasm and upon
activation, dissociates from HSP90, and translocates to the nu-Cell Mcleus to activate the transcription of target genes (Sumanase-
kera et al., 2003a, 2003b). Consistent with a role for HSP90 in
the regulation of PPARa activity, the HSP90 inhibitor 17DMAG
significantly enhanced glucagon-induced PPARa activity
(Figure 6A). Furthermore, we observed a physical interaction of
PPARa with HSP90 in the cytoplasmic fraction prepared from
primary murine hepatocyte cultures (Figure 6B). Moreover, the
ability of glucagon to reduce the cytoplasmic localization and en-
hance the nuclear expression of phosphorylated PPARa was
markedly enhanced in the presence of 17DMAG (Figure 6B).
Taken together, these data suggest that HSP90 is a chaperone
for PPARa in hepatocyte cytoplasm, and the HSP90-PPARa
interaction may regulate the extent of glucagon-dependent
PPARa activation in the nucleus.
To assesswhether the nuclear translocation of PPARawas as-
sociated with an increase in PPARa-dependent transcriptional
activity, hepatocytes were transfected with a luciferase reporter
gene containing three tandem copies of a PPRE. Glucagon
increased PPRE-dependent luciferase activity by more than
4.5-fold in WT hepatocytes (Figure 6C, p < 0.01). As the PPRE
integrates transcriptional responses from PPARa, PPARb, and
PPARg, we verified the importance of PPARa as a downstream
target of glucagon action using PPARa knockout (PPARa/)
mice. Indeed, the glucagon-stimulated induction of PPRE-de-
pendent luciferase activity was substantially diminished in
PPARa/ versus +/+ hepatocytes (Figure 6C, p < 0.01). Hence,
more than 70% of the glucagon-stimulated induction of PPRE
transcriptional activity in hepatocytes is mediated by PPARa.
This increase in PPARa activity upon glucagon stimulation was
lost in Gcgr/ hepatocytes (Figure S5A). Furthermore, gluca-
gon’s effect on PPARa activation in Gcgr+/+ hepatocytes was
similar and nonadditive to the stimulation of PPARa by the phar-
macological activator WY14-643 (Figure S5B), and prevented by
the PPARa antagonist GW6471 (Figure S5C). The glucagon-
stimulated PPARa activation was abolished by the p38 MAPK
inhibitor SB203580 (Figure 6D). Furthermore, fasting increases
PPARa interaction with p38MAPK in Gcgr+/+ mice, but not in
Gcgr/mice (Figure 6E), and this increased interaction is mim-
icked by glucagon (Figure 6F). These findings demonstrate that
glucagon activates PPARa in an AMPK- and p38 MAPK-depen-
dent pathway.
We next examined the expression of other transcription
factors involved in the regulation of hepatic lipid metabolism.
The changes in expression of SREBP1, PGC1a, and ChREBP
during fasting were not mimicked by glucagon administration,
and/or were not regulated by glucagon or Gcgr genotype in
a consistent manner in male and female mice (Figures S5D,
S5E, and S5F), whereas male and female mice display similar
phenotypes in terms of plasma lipid levels (Figures 1 and S1)
and gene expression (Figures 4 and S3) after fasting.
As FGF-21 and Acyl CoA Oxidase (ACO) have been identified
as downstream targets of PPARa capable of regulating fasting
lipid metabolism (Badman et al., 2007; Inagaki et al., 2007), we
assessed ACO and FGF-21 expression in Gcgr/ mice and
in WT mice treated for 24 hr with glucagon. Both mRNA tran-
scripts were induced in Gcgr+/+ liver after fasting (Figures S6A
and S6C); however, basal levels of both mRNAs were higher in
Gcgr/ versus Gcgr+/+ mice and did not increase further
with fasting (Figures S6A and S6C). Furthermore, glucagon hadetabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc. 363
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ures S6B and S6D). Additionally, circulating levels of FGF-21
were not significantly different after fasting in Gcgr/ versus
Gcgr+/+ mice, and glucagon administration had no effect on
levels of circulating FGF-21 in Gcgr+/+ mice (Figures S6E and
S6F). Hence, the effects of glucagon on hepatic lipid synthesis
and secretion are not associated with corresponding changes
in FGF-21 expression.
Glucagon Modulates Triglyceride Synthesis and FFA
Beta Oxidation in a PPARa-Dependent Manner
We next investigated the role of PPARa in the modulation of he-
patic lipid metabolism by glucagon. No significant difference in
FFA neosynthesis was observed in PPARa/ hepatocytes
under basal or glucagon-stimulated conditions (Figure 7A).
Although glucagon inhibited TG synthesis in +/+ hepatocytes,
glucagon failed to inhibit TG synthesis in PPARa/ hepato-
cytes (Figure 7B). In contrast the inhibitory effects of glucagon
on TG secretion were preserved in PPARa/ hepatocytes (Fig-
ure 7C, 50.3% inhibition in PPARa+/+ versus 35.2% inhibition in
PPARa/). Similarly, the hypolipidemic effect of glucagon on
levels of plasma FFA and TG as well as the glucagon-mediated
inhibition of hepatic triglyceride secretion was preserved in
PPARa/ mice (Figures S7A, S7B, and S7C).
PPARawas also essential for the ability of glucagon to regulate
FAO, as glucagon stimulated 14CO2 production in PPARa+/+
hepatocytes, but had no effect on FAO in PPARa/ mice
(Figure 7D). Furthermore, in contrast to the glucagon-regulated
FAOgeneexpressionprofileobserved in+/+mice (Figure4C), glu-
cagon failed tomodulate theexpressionofmultiplegenes involved
in FFA beta oxidation in PPARa/ mice (Figure S7D). Finally,
pharmacological activation ofPPARa in using fenofibrate restored
normal levels of FFAbetaoxidation inGcgr/ liver homogenates
(compare Figure 3D versus 6E), increasing FFA beta oxidation
by Gcgr/ liver homogenates to similar levels obtained with
Gcgr+/+ liver homogenates. Taken together, these findings
indicate that glucagon stimulates TG synthesis and FFA beta oxi-
dation in a PPARa-dependent manner, and is required for the ac-
tivation of PPARa-dependent metabolic pathways during fasting.
DISCUSSION
Glucagon levels are elevated in subjects with type 2 diabetes
and contribute to the development of excess hepatic glucose
production and hyperglycaemia. Accordingly, Gcgr antagonists
and antisense oligonucleotides (ASOs) directed against the
Gcgr are being assessed for the treatment of T2DM; however,
the consequences of blocking hepatic Gcgr signaling remain in-Cellcompletely understood. Our data demonstrate that in the fasted
state, glucagon action is essential for multiple pathways regulat-
ing lipid homeostasis. Furthermore, the actions of glucagon on
lipid metabolism are mediated predominantly through AMPK-,
p38 MAPK-, and PPARa-dependent mechanisms.
Analysisof lipidhomeostasis inGcgr/mice fasted for5hrdid
not reveal differences in levels of plasma TGs in Gcgr/ versus
Gcgr+/+ littermate controls, consistent with earlier findings (Gel-
ling et al., 2003). In contrast a marked increase in plasma TGs
was observed in Gcgr/mice after amore prolonged fast. Con-
sistent with the improvement in hyperglycemia, levels of plasma
and hepatic TGs were reduced in diabetic rodents following
reduction of hepatic Gcgr expression; in contrast, the levels of
plasmaand liver TGswereparadoxically increased in control non-
diabetic rats after ASO administration (Sloop et al., 2004). Simi-
larly, treatment of db/db mice for 3 weeks with Gcgr ASOs re-
sulted in a decrease in liver glycogen but a significant increase
in liver TGs in both the fasted and fed state (Liang et al., 2004).
Hence, the available evidence suggests that the hepatic TGaccu-
mulation observed in fasted Gcgr/ mice does not simply re-
flect abnormalities arising due to developmental loss of Gcgr
signaling, but rather implicates a relationship linking diminished
or absent Gcgr expression with the accumulation of hepatic TG.
FFA beta oxidation/ketogenesis is increased while lipogenesis
is decreased during fasting, a state characterized by reduced
levels of insulin and increased levels of glucagon and FFA. Stud-
ies using PPARa/mice have demonstrated the central impor-
tanceof PPARa signaling pathways for the control of the adaptive
metabolic response to fasting (Kersten et al., 1999). Remarkably,
Gcgr/ mice exhibit increased hepatic TG secretion following
fasting and enhanced susceptibility to hepatosteatosis following
exposure to a high-fat diet (Figure S8), features identical to those
previously described in studies of PPARa/ mice (Kersten
et al., 1999). Consistent with the importance of the Gcgr for the
adaptive response to fasting, we observed increased expression
of genes involved in beta oxidation and an increased capacity of
liver to oxidize FFA during the fasted state inGcgr+/+mice. How-
ever, this gene expression signature was abolished in Gcgr/
mice, which displayed defective oxidation of FFAs in both the
fed and fasted state. Conversely, administration of glucagon
further augmented the expression of genes regulating FAOand in-
creased FFA oxidation in WT hepatocytes. Hence, the results of
experiments employingeither lossor enhancedGcgr signaling im-
plicate anessential physiological role forGcgr signaling in the con-
trol of a gene expression program linking fasting to enhanced fatty
acid oxidation. Furthermore, our data demonstrate that glucagon
not only increases the capacity of hepatocytes to oxidize FFA but
also increases the availability of substrate for beta oxidation, asFigure 4. Hepatocyte Gene Expression Profiles following Fasting
(A–E) Real-time PCR was performed on RNA extracted from liver of male Gcgr/ and littermate control +/+ mice after 5 hr or 16 hr fasting (A, B, D, and E), and
fromWTmales repeatedly injected with glucagon as described in methods (C and F). The relative level of mRNA transcripts detected was normalized to levels of
GAPDH (A and B) or 18S (C). All data are mean ± SEM (n = 4–11 mice in each group) and P values are assessed by one-way ANOVA test for comparison of gene
expression * = p < 0.05; ** = p < 0.01; *** = p < 0.001 for differences in 5 hr versus 16 hr fasted mice (A, B, D, and E) or for vehicle versus glucagon-treated mice (C
and D). Facl2: fatty acid CoA ligase, long chain, 2; Decr2: 2-4-dienoyl-coenzyme A reductase 2, peroxisomal; CPT1a: carnitine palmitoyltransferase 1A; CPT2:
carnitine palmitoyltransferase 2; Acadm: acyl-coenzyme A dehydrogenase, medium chain; Ehhadh: enoyl-coenzyme A, hydratase/3-hydroxyacyl coenzyme A
dehydrogenase (peroxisomal bifunctional enzyme); Hadha: hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hy-
dratase (mitochondrial trifunctional protein), alpha subunit; Hadhb: hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme
A hydratase (mitochondrial trifunctional protein), beta subunit. Acly: ATP citrate lyase; Fas: fatty acid synthase; Mod: malic enzyme; Lce: long chain fatty acid
elongase; Acacb: acetyl-coenzyme A carboxylase beta; SCD1: stearoyl-coenzyme A desaturase 1.Metabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc. 365
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(A and B) Quantification of hepatic PPARamRNA transcripts frommale Gcgr/ versus Gcgr+/+ littermate controls fasted for 5 or 16 hr (A) or fromWTmale mice
following chronic glucagon administration (B). Data are mean ± SEM (n = 4–11 mice in each group).
(C) Total liver lysates from Gcgr+/+ and Gcgr/ either fed or fasted for 16 hr were subjected to western blot analysis as described in the Experimental Proce-
dures. * = p < 0.05 for levels of proteins in the fed versus fasted state. Data are mean ± SEM (n = 4 mice in each group).
(D) Immunofluorescence staining of PPARa protein in primary mouse hepatocytes cultured in vitro with or without 20 nM glucagon for 30 min.
(E) Nuclear (left panel) and cytoplasmic (right panel) fractions were purified from liver of Gcgr+/+ and Gcgr/ either fed or fasted for 16 hr, and nuclear proteins
were analyzed by western blotting as described in the Experimental Procedures. HSP90 (cytoplasmic fraction) and TATA-binding protein (TBP) (nuclear fraction)
were used as loading controls. No HSP90 was detectable in the nuclear fraction, and no TBPwas detectable in cytoplasmic fraction (data not shown); * = p < 0.05
for levels of proteins in the fed versus fasted state. Data are mean ± SEM (n = 4 mice in each group).
(F) Gel-shift motility assay was performed using nuclear extract from liver of Gcgr/ mice or littermate controls either fed or fasted for 16 hr, incubated with
a radiolabeled ACO probe as described in the Experimental Procedures. Data are mean ± SEM of four independent experiments. * = p < 0.05, ** = p < 0.01
for fed versus fasted mice.366 Cell Metabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc.
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Glucagon Action and Lipid MetabolismFigure 6. Glucagon Activates PPARa in a p38 MAPK- and AMPK-Dependent Manner
(A–D) Primary hepatocytes prepared from PPARa+/+ or PPARa/ mice (C) or from WT mice (A and D) were transfected with the PPAR-responsive luciferase
reporter pHD(X3)Luc, and further incubated for 24 hr with vehicle alone or 20 nM glucagon, with or without 10 mM SB203580 (D) or with or without 500 nM
17DMAG (A). Data are mean ± SEM of three experiments. ** = p < 0.01 for control versus glucagon-treated cells; ## = p < 0.01 for glucagon-stimulated
PPARa+/+ versus PPAR/ hepatocytes or glucagon treatment in control versus SB203580-treated hepatocytes. In (B), after 30 min stimulation with 20 nM
glucagon with or without 500 nM 17 DMAG, nuclear and cytoplasmic fractions were purified from primary WT hepatocytes. PPARa was immunoprecipitated
in each fraction and blotted for HSP90 (upper panel) or phosphoserine (lower panels) HSP90 (cytoplasmic fraction) and TATA-binding protein (TBP) (nuclear
fraction) were used as loading controls.
(E and F) PPARawas immunoprecipitated from liver lysate prepared fromGcgr+/+ andGcgr/ fed or fasted for 16 hr (E), or fromWTmice injectedwith glucagon
(F), then subjected to western blot analysis using an anti-p38 MAPK antibody. Total p38MAPK in total lysate is shown as a loading control.Cell Metabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc. 367
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stimulation when FFA beta oxidation is inhibited by etomoxir.
Glucagon is known to suppress lipogenesis in part via repres-
sion of sterol regulatory element-binding protein-1c (SREBP-1c)
expression (Foretz et al., 1999). Moreover, exogenous glucagon
stimulates cyclic AMP formation and cAMP response element-
bindingprotein (CREB) activation, leading tocontrol of a lipogenic
gene expressionprogram in aPPARg-dependentmanner (Herzig
et al., 2003). Recent studies have implicated a role for exogenous
glucagon in thecontrol of lipogenesis via ap38MAPK-dependent
manner (Xiong et al., 2007). Inhibition of p38 leads to enhanced
TGaccumulation in fat-fedmice, togetherwith increased expres-
sion of genes promoting hepatic lipogenesis. Conversely, exog-
enous glucagon reduced levels of SREBP-1c, SREBP-2, FAS,
HMG CoA-R, and FPS mRNA transcripts in hepatocytes in
a p38-dependent manner (Xiong et al., 2007). Although we also
observed that glucagon reduced TG synthesis and fasting de-
creased expression of mRNA transcripts for lipogenic enzymes
Figure 7. Glucagon Increases FAO and Inhibits TG
Synthesis in a PPARa-Dependent Manner
(A–C) Lipid synthesis was assessed by measurement of FFAs
and TGs in hepatocytes fromWT and PPARa/mice treated
for 16 hr with or without 20 nM glucagon. Lipids were
extracted from the media (secretion) or cells + media (synthe-
sis), separated by TLC, and quantified by scintillation count-
ing. Data are mean ± SEM of four independent experiments.
* = p < 0.05, *** = p < .001 for values obtained in the presence
or absence of glucagon.
(D) Beta oxidation of [14C]-palmitate assessed in primary
hepatocytes from WT or PPARa/ mice and treated with
or without 20 nM glucagon for 24 hr as described in the Exper-
imental Procedures. Data are mean ± SEM. of four indepen-
dent experiments. * = p < 0.05 for values obtained in the pres-
ence or absence of glucagon.
(E) Beta oxidation of [1-14C]-palmitate assessed in liver
homogenates prepared from Gcgr/ fasted for 24 hr with
or without fenofibrate administration during fasting as
described in the Experimental Procedures. Data are mean ±
SEM of six independent experiments. * = p < 0.05 for vehicle
versus glucagon treated cells in (C).
in Gcgr+/+ mice, loss of Gcgr signaling had no im-
pact on the fasting-associated reduction in the lipo-
genic gene expression program. Hence, although
glucagon may act pharmacologically to control li-
pogenesis through SREBP-1c and p38 MAPK, en-
dogenous Gcgr signaling does not appear to be es-
sential for suppression of a lipogenic gene
expression program during fasting. Instead, gluca-
gon directs FFA mobilized from TG stores toward
beta oxidation rather than reesterification into tri-
glyceride and secretion.
Classic concepts of glucose homeostasis impli-
cate a central role for glucagon in the fasting state
to promote enhanced gluconeogenesis and glyco-
genolysis. Levels of both circulating glucagon and
hepatic PPARa mRNA transcripts are increased by
fasting and repressed by glucose (Lefebvre et al.,
2006). Fasting is also associated with enhanced
TG lipolysis, increased levels of FFA, and increased hepatic fatty
acid oxidation, thereby enhancing the availability of fuel sub-
strates for use in peripheral tissues. Our current data extendphys-
iological concepts of glucagon action by demonstrating that Gcgr
signaling activates a p38MAPK- and PPARa-dependent signaling
network to enhance fatty acid oxidation. Moreover, disruption of
endogenousGcgr signaling impairs the control of fatty acid oxida-
tionduring fasting. Thesefindings, summarized inFigureS9, taken
togetherwith our observations thatGcgr/mice rapidlydevelop
hepatosteatosis following high-fat feeding (Figure S8) may have
implications for therapeutic strategies designed to attenuate
Gcgr signaling for the treatment of type 2 diabetes.
EXPERIMENTAL PROCEDURES
Animals, Treatments and Reagents
Experiments were carried out using 8- to 12-week-old global Gcgr/ mice
and age and sex-matched littermate control mice in the C57BL/6 background368 Cell Metabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc.
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ings, we observed that food intake and body weight was similar in Gcgr/
and Gcgr+/+ littermate control mice (Gelling et al., 2003). For experiments
employing PPARa/ mice (Jackson Laboratory), age- and sex-matched
129S1/SvImJmice were used asWT controls (8 to 12 weeks of age) according
to Jackson Laboratory recommendation. All mouse strains were maintained
on standard rodent chow (unless otherwise indicated) under a normal 12 hr
light/12 hr dark cycle. All experiments were conducted according to protocols
and guidelines approved by the Toronto General Hospital Animal Care Com-
mittee. Tominimize the potential influence of circadian rhythms on experimen-
tal outcomes, standardized periods of fasting or experimental analyses were
utilized. To test the effect of insulin, WT mice fasted for 5 hr were given
0.7 U/kg of human insulin (Novolin GE, Novo Nordisk) by intraperitoneal injec-
tion. To test the effect of repeated glucagon administration, mice were injected
subcutaneously (sc) with glucagon (30 mg/kg body weight in 500 ml of 10%
gelatine) or 10% gelatine alone, involving a total of four injections over a 24 hr
period. Mice were euthanized 1 hr after the last injection; blood was obtained
via cardiac puncture; and liver samples were collected, snap frozen in liquid
nitrogen, and stored at 80C until further analysis. For acute glucagon injec-
tions, mice were fasted for 5 hr, then injected with glucagon (30 mg/kg body
weight via sc injection) in 500 ml of 10% gelatin or with vehicle alone (10%
gelatin). H89, SB 203580, and AMPKi were from Calbiochem, San Diego, CA
and Etomoxir was from Sigma Aldrich, St. Louis, MO.
In Vivo Hepatic TG Secretion
After fasting and/or glucagon administration, mice were injected via the tail
vein with Triton WR-1339 (0.5g/kg diluted 15% in PBS pH 7.4). Blood samples
(50 mL) were collected prior to IV injection and at 30 min, 1, 2, and 3 hr after
injection.
Biochemical Studies
Blood samples were collected by cardiac puncture or tail vein. For plasma
preparation, blood samples were supplemented with trasylol, EDTA, and
diprotin and centrifuged at 6,000 rpm at 4C for 5min. FFA and TGs weremea-
sured using colorimetric assays (NEFA Kit and L-Type TG Kit,Wako Chemicals
[Richmond, VA]). Insulin levels were determined using a mouse ultrasensitive
insulin Elisa (Alpco Diagnostic). Blood glucose levels were measured using
a Glucometer (Ascensia; Bayer HealthCare). FGF21 levels were assessed by
radioimmunoassay (Phoenix Pharmaceuticals, Inc.).
Real-Time PCR Analysis of Gene Expression
RNA was extracted from liver using Trizol Reagent according to manufacturer
instructions (Sigma-Aldrich, St. Louis, MO). Real-time quantitative PCR reac-
tions were carried out using the TaqMan Gene Expression Assay Universal
PCR Master Mix (Applied Biosystems; Foster City, CA) and an ABI Prism
7900 Sequence Detection System (Applied Biosystems; Melbourne, Aus-
tralia). Values for hepatocyte mRNA transcripts were normalized to the levels
of GAPDH, as levels of GAPDH mRNA transcripts were not different between
Gcgr+/+ and Gcgr/mice and did not change following a 5 or 16 hr fast. Rel-
ative values for hepatocyte mRNA transcripts after glucagon administration
were obtained by normalizing levels of mRNA transcripts to the levels of 18S
rRNA in the same RNA samples, as glucagon administration increased levels
of GAPDH mRNA transcripts.
Primary Murine Hepatocyte Cultures
Murine hepatocytes were isolated as previously described (Flock et al., 2007),
seeded in Primaria plates (BD Biosciences; Mississauga, ON) and allowed to
attach for 2 to 4 hr prior to experimental treatments.
Lipid Synthesis and Secretion in Hepatocytes
Cells were labeled with [H3]acetate (5 mCi/ml) in Williams E medium + 5% FBS
for 16 hr and lipids were extracted twice with hexane:isopropanol 3:2 (v/v), the
organic solvent was evaporated, and lipids were resuspended in hexane and
spotted on a TLC plate. Neutral lipids were separated using ether:diethyl
ether:glacial acetic acid 90:10:1 (v/v/v). Zones corresponding to the lipid stan-
dard were cut, mixed in scintillation cocktail overnight with gentle agitation,
and counted on a Packard liquid scintillation counter. After lipid extraction,
cells were digested in 1ml of 50mMNaOH and used for protein determination.CellPPRE-Luciferase Activity
The PPAR-activated firefly luciferase reporter pHD(X3)Luc, obtained from
Dr. J. Capone (McMaster University; Toronto, ON, Canada), contains three
tandem copies of the PPRE from the rat enoyl-CoA hydratase/3-hydrox-
yacyl-CoA dehydrogenase gene upstream of a minimal promoter cloned into
the plasmid pCPS-luc. (Zhang et al., 1993). After transfection of the reporter
plasmid in Williams E media with lipofectamine 2000 at a ratio 1:3 (mL lipofect-
amine 2000: mg plasmid) for 5 hr, hepatocytes (1 million per well in 6-well
plates) were treated with 20 nM glucagon and/or 10 mM SB203580. After
24 hr, cells were washed three times in ice-cold PBS and lysed in 250 ml of
harvest buffer (50 mM Tris/MES pH 7.8, 0.1% Tritton X-100, 1 mM DTT).
Luciferase activity was determined using 200 ml of cell lysate by adding 5 ml
of luciferase cocktail (150 mM Tris/MES 1 M pH 7.8, 150 mM MgOAc, and
40 mM ATP), and luminescence was assessed in a Berthold Tube Luminome-
ter LB-9507. An aliquot of cell lysate was used for total protein determination.
Preparation of Nuclear Extracts and EMSA Assays
Liver tissue (approximately 50 mg) was minced in 500 ml of homogenization
buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA pH 7.4, 0.1 mM
EGTA, 1 mM DTT, and protease and phospatase inhibitors). Homogenates
were dounced20 times (pestle B) and incubated on ice for 30minprior to adding
6% of nonidet P40 10%. After an additional 30 min incubation on ice, homoge-
nateswerecentrifuged for 1minat13000 rpmat4C.Thepellet containingnuclei
was resuspended in 100 ml of buffer containing 20 mM HEPES pH 7.9, 400 mM
NaCl, 1 mM EDTA pH 7.4, 1 mM EGTA, 1 mM DTT, and 5% glycerol, supple-
mented with protease and phosphatase inhibitors. Nuclei were incubated for
30minon ice, andhomogenateswere vortexed every 10min for 10 s.After a final
1mincentrifugationat 13,000 rpmat 4C,protein concentrationdetermination in
supernatant was performed as described previously (Rodriguez et al., 2000).
Immunohistochemistry
Primary hepatocytes were seeded in fibronectin-coated glass slide chambers.
After 24 hr culture in Williams E media without serum but supplemented with
2 mM Glutamax, 100 U/ml penicillin, and 100 mg/mL streptomycin, cells were
stimulated with 20 nM glucagon for 30 min, after which cells were fixed for 1 hr
at room temperature in 4% formaldehyde. After 1 hr blocking in PBST + 10%
donkey serum, cells were incubated overnight in a humidified chamber with
anti-PPARa antibody (Santa Cruz Biotechnology; Santa Cruz, CA) diluted 1/
100 in PBS:1% Triton + 5% bovine serum albumin (BSA). Cells were then incu-
bated for 1 hr at room temperature with Cy2-conjugated donkey anti-rabbit IgG,
stained with 40,6-diamidino-2-phenylindole (DAPI) (1:50,000 in PBS for 15 min),
and mounted using Dako fluorescent mounting medium (DakoCytomation
Canada; Ontario, Canada). Cells were visualized using an Olympus FluoView
FV1000microscopeanda63Xoil immersionobjective, usingsequential capture.
Western Blot Analysis
Primary mouse hepatocytes were serum-starved for 24 hr in Williams E media
supplementedwith 2mMGlutaMAX, 100 U/ml penicillin, and 100 mg/mL strep-
tomycin, then stimulated with 20 nM glucagon in the presence or absence of
signal transduction inhibitors added 30 min prior to glucagon. The experiment
was terminated by transferring the plates onto ice and washing the cells with
ice-cold PBS, and protein samples were prepared as described (Koehler
and Drucker, 2006). Antibodies against PPARa (Fitzgerald Industries Intl.; Con-
cord, MA), phospho-p38 MAPK (Thr180/Tyr182), phospho-AMPKa (Thr172),
total p38 MAPK, and total AMPK (Cell Signaling Technology; Beverly, MA)
were used according to the manufacturer’s instructions. Densitometry was
performed on blots exposed on Biomax MR films (Eastman Kodak Co.) using
a Hewlett-Packard ScanJet 3p scanner and NIH Image software.
p38 MAPK Activity and Protein Analyses
Cells were lysed in 20 ml of lysis buffer, and p38MAPK assaywas performed on
10 ml of lysate using the TruLight p38a Kinase Assay Kit (Calbiochem, La Jolla,
CA), according to manufacturer instructions. Cell protein content was mea-
sured using BCA kit (Pierce; Rockford, IL), with BSA as the standard.
shRNA-Mediated Knockdown of p38MAPK and AMPK
shRNA plasmid and Trans-lentiviral packaging system were purchased from
Open Biosystem (Huntsville, AL). Lentivirus production and hepatocytesMetabolism 8, 359–371, November 5, 2008 ª2008 Elsevier Inc. 369
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thesis and FFA beta oxidation assays were done 36 hr after infection, as de-
scribed above and below.
FFA Beta Oxidation in Hepatocytes
FFA oxidation was assessed by measuring the production of 14CO2 from
[1-14C]palmitate. Briefly, hepatocytes (1 million in a 6 cm plate) were incubated
for 24 hr in serum-free Williams E medium containing 20 nM glucagon with or
without signal transduction inhibitors. Plates were then washed with warm
PBS and 2 ml of beta oxidation media (1 mM palmitate bound to fatty acid-
free albumin at a molar ration 5:1 in Williams E medium, 0.3 mCi/mL 1-14C pal-
mitate (Amersham Biosciences; Piscataway, NJ) with or without glucagon
and/or inhibitors was added. Each petri dish was sealed with parafilm onto
the inside of which a Whatman paper wet with 100 ml of phenylethylamine/
methanol (1:1) was taped to trap the CO2 produced during the incubation pe-
riod. After a 2 hr incubation period, 200 ml of H2SO4 (4 mol/l) was added to the
cells, which were then further incubated for 1 hr at 37C. Finally, the seal was
removed from each petri dish, and the pieces of Whatman paper were trans-
ferred to scintillation vials for determination of radioactivity. An aliquot ofmedia
was counted to determine the total radioactivity.
FFA Beta Oxidation in Liver Homogenates
Half a gramof liverwasmanually homogenizedusing aPotter-Elvejhemhomog-
enizer in 10 ml of ice-cold isolation buffer (220 mM mannitol, 70 mM sucrose,
2 mM HEPES, and 0.1 mM EDTA at pH 7.4). Aliquots of homogenate (300 ml)
were added to 1.7 ml of reaction medium (50 mM sucrose, 150 mM Tris-HCl,
20 mM KH2PO4, 10 mM MgCl2-6H2O, 2 mM EDTA, 1 mM L-carnitine, 0.2 mM
CoA, 2 mM NAD, 0.1 mM malate, 10 mM ATP, 1 mM Palmitate complexed to
fatty acid-free albumin at a 5:1 molar ratio in Williams E medium, 0.3 mCi of
[1-14C]-palmitate [Amersham Biosciences], pH 7.4). Reactions performed in
a sealed flask were allowed to proceed for 30 min in a shaking water bath at
37C. Incubations were terminated by the addition of 1 ml of 3 M perchloric
acid to the reactionmediumtoprecipitateproteinandnonmetabolizedpalmitate
and then further incubated at room temperature for 2 hr for collection of 14CO2
into a suspended well containing 500 ml of ethanolamine. Blanks were prepared
by acidification of the reaction medium immediately after the addition of the
homogenate. Radioactivity in CO2 was quantified by liquid scintillation
spectrometry.
Statistical Analysis
Statistical significance was assessed by one-way or two-way ANOVA using
Bonferroni’s multiple comparison posttest and, where appropriate, by
unpaired Student’s t test using GraphPad Prism 4 (GraphPad Software; San
Diego, CA). A p value < 0.05 was considered to be statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include nine figures and can be found online at http://www.
cell.com/cellmetabolism/supplemental/S1550-4131(08)00292-1.
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